Op-Ed: We Can’t Let Drug Companies Get Out of Negotiating Prices

The authors outline and refute some of the most prominent legal claims raised by drug manufacturers in litigation against Medicare drug price negotiation. Each of these claims suggests a concerning belief that some private companies have a right to public funds—a belief that courts should reject as price negotiation litigation moves forward.